
Prolexys Pharmaceuticals wouldn't necessarily characterize proteins as difficult to characterize, especially not if it's using the technology it developed. The biotech research firm's HySpec and HyNet are high-throughput systems for protein expression, purification, and analysis. Prolexys, formerly known as Myriad Proteomics, has also developed its own bioinformatics to put together protein interaction maps from the data generated by HySpec and HyNet. The company has been focusing on cancer research, working with groups such as Columbia University and the Tower Cancer Research Foundation to study advanced solid tumors. Myriad Genetics spun off Prolexys, which was founded in 2001, as a private company in 2003.

Quality Assured Services (QAS) is a direct marketer of point-of-care and self-testing diagnostic products. It distributes easy-to-use diagnostic kits directly to consumers' homes, as well as to health professionals and home health care providers. Its products include anticoagulation tests, cholesterol tests, and other products that monitor and diagnose such conditions as blood pressure, diabetes, lung function, and infectious diseases. The company also provides telemedicine support, patient management software, insurance verification, and billing services. QAS is a subsidiary of diagnostic products firm Inverness Medical Innovations.

Symbollon is a specialty pharmaceutical company focused on the development and commercialization of proprietary drugs based on its I2 technology. I2 is the chemical symbol for molecular iodine. Molecular iodine is the active species of iodine, a proven fast acting, broad-spectrum antimicrobial and therapeutic. Formed in 1986, Symbollon completed its initial public offering in December 1993. Since that time we have pursued product applications for our technology in two distinct areas; women’s healthcare and antimicrobial applications.In female health, Symbollon has developed a proprietary oral tablet based on our technology that generates I2 in situ (the stomach of the patient). We refer to this drug as IoGen. In 2000, Symbollon completed Phase I and II clinical trials evaluating IoGen as a potential treatment for fibrocystic breast disease. Phase III pivotal trials will be conducted in 2005. We believe that IoGen may also be useful for the treatment and prevention of other types of excess cell growth in female reproductive tissue, such as endometriosis, ovarian cysts and pre-menopausal breast cancer.

Eurand N.V. company was formerly known as Eurand B.V. Eurand N.V. was incorporated in 1984 and is based in Amsterdam, the Netherlands. Eurand N.V., a specialty pharmaceutical company, develops, manufactures, and commercializes pharmaceutical and biopharmaceutical products. The company develops these products based on its proprietary customized release technologies used to reduce daily dosing requirements and time the release of drugs in the body to increase efficacy or to reduce side effects; Tastemasking/ODTs technologies to increase patient compliance through more convenient dosage forms, such as orally disintegrating tablets and taste-masked drugs; bioavailability enhancement technologies to improve drug absorption; and drug conjugation technologies to extend drug half-life and to target specific organs or other biological targets, such as tumors. Its technologies are used for applications in drug products used for various therapeutic areas, including cardiovascular, gastrointestinal, pain, nutrition, and respiratory.Eurand company offers EUR-1037, as an over-the-counter sleep-aid; EUR-1025, an oral formulation of ondansetron, an anti-emetic prescribed to prevent nausea and vomiting; and EUR-1073, an enteric coated, controlled release formulation of beclomethasone diproprionate for the treatment of inflammatory bowel disease. It products also include Zentase, also known as EUR-1008, a porcine-derived proprietary enzyme replacement product for the treatment of exocrine pancreatic insufficiency, which has completed Phase III clinical trials; Amrix, a sustained release formulation of cyclobenzaprine hydrochloride, used as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute and painful musculoskeletal conditions; and products and services to the cystic fibrosis community.

Telik, Inc. company was founded in 1988 and is based in Palo Alto, California. Telik, Inc., a clinical stage drug development company, focuses on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. Telik company's advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the discovery of small molecule drug candidates.

BioTrove, researchers can mine the treasure trove of information encoded in genetic material... and still make it home in time for dinner. The company makes the OpenArray life science research systems that allow scientists to rapidly prepare and test multiple genetic samples at once. The system can perform more than 3,000 genetic tests simultaneously on a single slide and is used by laboratory researchers in gene expression and genotyping analysis. BioTrove was acquired by Life Technologies in late 2009. At the same time, the company's RapidFire sample preparation business was spun off into a new entity named BIOCIUS Life Sciences.

Mirus Bio provides gene transfer technologies to the pharmaceutical industry. The company's reagent kits assist researchers with in vitro transfection, in vivo delivery, DNA and RNA labeling, and RNA interference. Besides its kits, Mirus Bio is also developing its own therapies based on its intravenous technology, called Pathway IV, that facilitates the delivery of plasmid DNA to targeted muscles. One of those therapies is MyoDys, a gene therapy designed to treat muscular dystrophy by delaying loss of muscle function. Mirus Bio is also developing treatments for peripheral ischemia and anemia. Mirus Bio has agreed to be acquired by Roche Holding for $125 million.

pSivida Corp. company was founded in 1987 and is based in Watertown, Massachusetts. pSivida Corp., together with its subsidiaries, develops drug delivery products in the healthcare sector. It develops products utilizing its proprietary technologies, including Durasert, BioSilicon, CODRUG, and Medidur. The company's products include Retisert for the treatment of posterior uveitis; and Vitrasert for the treatment of AIDS-related cytomegalovirus retinitis. Its products also include Iluvien, a Phase III clinical trial product for the treatment of diabetic macular edema; and Durasert and Iluvien, which are under pre-clinical trials to treat retinitis pigmentosa and age-related macular degeneration. In addition, pSivida Corp. owns the rights to develop and commercialize a modified form of silicon, known as BioSilicon, which has therapeutic applications for treatment of cancer. Its lead BioSilicon product is BrachySil, which is in Phase II clinical trial for the treatment of pancreatic cancer. The company primarily operates in the United Kingdom and the United States. It has strategic collaborations with Chiron Vision Corporation; Bausch & Lomb Incorporated; Alimera Sciences, Inc.; Pfizer, Inc.; and Intrinsiq Materials Cayman Limited.

Genentech, Inc. (Genentech) is a biotechnology company that discovers, develops, manufactures and commercializes pharmaceutical products to treat patients with unmet medical needs. It commercializes multiple biotechnology products and also receives royalties from companies that are licensed to market products based on the Company’s technology. Genentech commercializes various products in the United States, including Avastin, Rituxan, Herceptin, Lucentis, Xolair, Tarceva, Nutropin, Activase, TNKase, Cathflo Activase, Pulmozyme and Raptiva. The Company’s licensed products include Trastuzumab, Rituximab, Bevacizumab, Dornase alfa, recombinant, Alteplase and Tenecteplase, Somatropin, Daclizumab, Ranibizumab, Etanercept, Adalimumab and Infliximab. In March 2009, Roche Holding Ltd. completed the acquisition of Genentech.

Virbac Corporation makes animal health and pet-care products and sells them to veterinarians and retailers. For dogs and cats it makes C.E.T dental products, Allederm dermatological products, and digestive and hairball remedies. The company's Iverhart medication prevents heartworms in dogs. Virbac also makes antibiotics, dewormer, and euthanasia products. Its other brands include Biomox, Clintabs, and Vetasyl. In addition to producing its own animal health products, the company provides contract manufacturing through subsidiary PM Resources. The company is owned by Virbac SA.
Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.







.webp)
.webp)
.webp)
.webp)
.webp)







